Skip to content

Posterior Nasal Nerve (PNN) Rhinitis Study

Clinical Evaluation of Low Power Radiofrequency Energy Applied to the Posterior Nasal Nerve Area for Symptomatic Relief of Chronic Rhinitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03727347
Enrollment
50
Registered
2018-11-01
Start date
2018-10-16
Completion date
2020-09-17
Last updated
2021-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinitis

Brief summary

Evaluation of the Aerin Medical Device used for the treatment of chronic rhinitis

Detailed description

This is a non-significant risk, prospective, multi-center, non-randomized study to evaluate the safety and efficacy of the Aerin Medical device (InSeca Stylus) when used to deliver radiofrequency (RF) energy to the posterior nasal nerve area to improve symptoms in those diagnosed with chronic rhinitis.

Interventions

DEVICEInSeca Stylus

Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).

Sponsors

Aerin Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All enrolled subjects will be treated with the InSeca Stylus

Eligibility

Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 22 to 75 years (inclusively) 2. Willing and able to provide informed consent 3. Willing and able to comply with the subject-specific requirements outlined in the study protocol 4. Seeking treatment for chronic rhinitis symptoms of at least 6 months duration and willing to undergo an office-based procedure 5. Moderate to severe symptoms of rhinorrhea (rTNSS rating of 2 or 3 for rhinorrhea) 6. Mild to severe symptoms of nasal congestion (rTNSS rating of 1, 2 or 3 for congestion) 7. rTNSS score of greater than or equal to 6 8. Dissatisfaction with medical management, defined as usage of intranasal steroids for a minimum of 4 weeks without adequate symptom relief, as judged by the subject

Exclusion criteria

1. Anatomic obstructions that in the investigator's opinion limit access to the posterior nose 2. Altered anatomy of the posterior nose as a result of prior sinus or nasal surgery or injury 3. Active nasal or sinus infection 4. Moderate to severe ocular allergic symptoms (such as eye tearing \[epiphora\], itching \[pruritus\], or redness \[erythema\]) 5. History of significant dry eye 6. History of any of the following: nose bleeds in the past 3 months, rhinitis medicamentosa, head or neck irradiation 7. Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session 8. Known or suspected to be pregnant, or is lactating 9. Participating in another clinical research study 10. Other medical conditions which in the opinion of the investigator would predispose the subject to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study

Design outcomes

Primary

MeasureTime frameDescription
Change in Reflective Total Nasal Symptom Score (rTNSS)Comparison of scores at Baseline and 12 weeks post procedureMean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value. The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit
Percentage of Participants With Treatment Related Adverse Events (Safety)At or following the study procedure, and up to the final study visit at 1 year.Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure. This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure.

Other

MeasureTime frameDescription
rTNSS Responder RateComparison of scores at Baseline and 12 weeks post procedureThe Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected.
Change in rTNSS Over TimeBaseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity. The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded.
Change in rTNSS Individual Nasal Symptom Component Scores Over TimeBaseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedureReflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity.
Response on Aerin Quality-of-Life (QOL) Assessment ItemsThe QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative. Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response.

Countries

United States

Participant flow

Recruitment details

Patients in the specialist's clinic seeking treatment for chronic rhinitis symptoms of at least 6 months duration were approached for possible participation. Following completion of the informed consent process, baseline evaluation was conducted.

Pre-assignment details

Three potential subjects failed to meet one or more of the inclusion/exclusion criteria.

Participants by arm

ArmCount
InSeca Stylus Treatment Group
Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
50
Total50

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up1
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicInSeca Stylus Treatment Group
Age, Continuous57.9 years
STANDARD_DEVIATION 11.9
Body Mass Index29.8 kg/m2
STANDARD_DEVIATION 6.4
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
49 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
47 Participants
Region of Enrollment
United States
50 participants
rTNSS8.5 score on a scale
STANDARD_DEVIATION 1.8
Sex: Female, Male
Female
29 Participants
Sex: Female, Male
Male
21 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 50
other
Total, other adverse events
31 / 50
serious
Total, serious adverse events
2 / 50

Outcome results

Primary

Change in Reflective Total Nasal Symptom Score (rTNSS)

Mean change in Reflective Total Nasal Symptoms Score (rTNSS) from baseline to 12 weeks post-study procedure. Improvement (12 week score - baseline score) is signified by a negative value. The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. This study will measure the mean change in the rTNSS total score from Baseline to 12 week follow up visit

Time frame: Comparison of scores at Baseline and 12 weeks post procedure

Population: The analyzed population excludes one subject who did not complete the rTNSS questionnaire at the 12 week follow-up visit due to oversight.

ArmMeasureValue (MEAN)Dispersion
InSeca Stylus Treatment GroupChange in Reflective Total Nasal Symptom Score (rTNSS)-5.1 units on a scaleStandard Deviation 2.6
p-value: <0.0001t-test, 2 sided
Primary

Percentage of Participants With Treatment Related Adverse Events (Safety)

Characterization of the type and frequency of treatment-related adverse events reported during or following the study procedure. Subjects were asked about possible side effects or adverse experiences related to the study procedure at each follow up visit. Each event was documented and identified as to its relationship and level of relatedness to the study device and/or study procedure. This measure includes any subject who experienced at least one event considered definitely, probably, or possibly related to the device or procedure.

Time frame: At or following the study procedure, and up to the final study visit at 1 year.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InSeca Stylus Treatment GroupPercentage of Participants With Treatment Related Adverse Events (Safety)8 Participants
Other Pre-specified

Change in rTNSS Individual Nasal Symptom Component Scores Over Time

Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients will report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Scores from each of the four components of the questionnaire (rhinorrhea, nasal congestion, nasal itching, and sneezing) will be evaluated at each follow up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure. Individual component scores can range from 0 to 3, with a higher score indicating increased symptom severity.

Time frame: Baseline to each Follow Up visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure

ArmMeasureGroupValue (MEAN)Dispersion
InSeca Stylus Treatment GroupChange in rTNSS Individual Nasal Symptom Component Scores Over TimeRhinorrhea2.5 score on a scaleStandard Deviation 0.5
InSeca Stylus Treatment GroupChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Congestion2.5 score on a scaleStandard Deviation 0.6
InSeca Stylus Treatment GroupChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Itching1.7 score on a scaleStandard Deviation 0.9
InSeca Stylus Treatment GroupChange in rTNSS Individual Nasal Symptom Component Scores Over TimeSneezing1.9 score on a scaleStandard Deviation 0.8
Treatment Group - 2 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeRhinorrhea1.6 score on a scaleStandard Deviation 0.9
Treatment Group - 2 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Itching0.7 score on a scaleStandard Deviation 0.8
Treatment Group - 2 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Congestion1.5 score on a scaleStandard Deviation 1
Treatment Group - 2 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeSneezing1.0 score on a scaleStandard Deviation 0.7
Treatment Group - 4 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Congestion1.1 score on a scaleStandard Deviation 0.8
Treatment Group - 4 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeRhinorrhea1.2 score on a scaleStandard Deviation 0.8
Treatment Group - 4 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeSneezing0.8 score on a scaleStandard Deviation 0.6
Treatment Group - 4 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Itching0.4 score on a scaleStandard Deviation 0.6
Treatment Group - 12 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeSneezing0.9 score on a scaleStandard Deviation 0.8
Treatment Group - 12 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeRhinorrhea1.0 score on a scaleStandard Deviation 0.7
Treatment Group - 12 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Congestion1.1 score on a scaleStandard Deviation 0.8
Treatment Group - 12 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Itching0.5 score on a scaleStandard Deviation 0.7
Treatment Group - 26 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeSneezing0.8 score on a scaleStandard Deviation 0.7
Treatment Group - 26 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeRhinorrhea0.9 score on a scaleStandard Deviation 0.8
Treatment Group - 26 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Itching0.5 score on a scaleStandard Deviation 0.7
Treatment Group - 26 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Congestion1.1 score on a scaleStandard Deviation 0.8
Treatment Group - 52 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Congestion1.2 score on a scaleStandard Deviation 1
Treatment Group - 52 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeRhinorrhea1.1 score on a scaleStandard Deviation 0.8
Treatment Group - 52 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeNasal Itching0.5 score on a scaleStandard Deviation 0.7
Treatment Group - 52 Week DataChange in rTNSS Individual Nasal Symptom Component Scores Over TimeSneezing0.8 score on a scaleStandard Deviation 0.8
Other Pre-specified

Change in rTNSS Over Time

Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores range from 0 to 12. A higher score indicates increased symptom severity. The mean change in the rTNSS total score from Baseline to each follow up visit: 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure will be recorded.

Time frame: Baseline to each Follow Up Visit at 2 weeks, 4 weeks, 12 weeks, 26 weeks and 52 weeks post procedure.

Population: 50 subjects were enrolled. 2 week evaluation: 1 subject missed it due to unrelated illness. 4 week evaluation: 1 subject missed it due to travel; 1 other attended the visit but did not complete the questionnaire. 12 week evaluation: All subjects attended but 1 subject did not complete the questionnaire. 26 week evaluation: 2 subjects withdrew from the study prior to the visit. 52 week evaluation: 1 additional subject was lost to follow-up.

ArmMeasureValue (MEAN)Dispersion
InSeca Stylus Treatment GroupChange in rTNSS Over Time8.5 score on a scaleStandard Deviation 1.8
Treatment Group - 2 Week DataChange in rTNSS Over Time4.8 score on a scaleStandard Deviation 2.4
Treatment Group - 4 Week DataChange in rTNSS Over Time3.6 score on a scaleStandard Deviation 2.1
Treatment Group - 12 Week DataChange in rTNSS Over Time3.4 score on a scaleStandard Deviation 2.3
Treatment Group - 26 Week DataChange in rTNSS Over Time3.3 score on a scaleStandard Deviation 2.1
Treatment Group - 52 Week DataChange in rTNSS Over Time3.6 score on a scaleStandard Deviation 2.3
Other Pre-specified

Response on Aerin Quality-of-Life (QOL) Assessment Items

This Quality-of-Life (QOL) instrument is a 9-item patient self-reported questionnaire developed by Aerin Medical to gain understanding of the impact of chronic rhinitis on daily activities, feelings, symptoms and medication use. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative. Section 1 asks Please indicate how often you experience the following for 6 items. For items 1, 3, 4 and 5, those who answered never/rarely were considered to have a positive (favorable) response. For questions 2 and 6, those who answered frequently/very frequently were considered to have a positive (favorable) response. Section 2 requests Please indicate how often you use each of the following products to help you with your chronic rhinitis. For 3 items in this section, those who answered never/rarely were considered to have a positive (favorable) response.

Time frame: The QOL was to be completed by the subject at baseline prior to the treatment procedure, and at the 12 week, 26 week and 52 week visits post procedure.

Population: The baseline QOL was not completed by 4 subjects enrolled in the study. 12 week evaluation: 2 subjects failed to complete the QOL. 26 week evaluation: 2 subjects withdrew from the study prior to the 26 week visit. 52 week evaluation: 1 additional subject was lost to follow-up at this visit.

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessNeutral or Negative response36 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessPositive (favorable) response10 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayNeutral or Negative response43 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsNeutral or Negative response5 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityNeutral or Negative response39 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityPositive (favorable) response7 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysNeutral or Negative response37 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysPositive (favorable) response9 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightPositive (favorable) response11 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepPositive (favorable) response5 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsNeutral or Negative response36 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsPositive (favorable) response10 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightNeutral or Negative response35 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsPositive (favorable) response41 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingNeutral or Negative response22 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepNeutral or Negative response41 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingPositive (favorable) response24 Participants
InSeca Stylus Treatment GroupResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayPositive (favorable) response3 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightPositive (favorable) response28 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepPositive (favorable) response23 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepNeutral or Negative response25 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightNeutral or Negative response20 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayPositive (favorable) response17 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayNeutral or Negative response31 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityPositive (favorable) response30 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityNeutral or Negative response18 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessPositive (favorable) response38 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessNeutral or Negative response10 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingPositive (favorable) response36 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingNeutral or Negative response12 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsPositive (favorable) response20 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsNeutral or Negative response28 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysPositive (favorable) response24 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysNeutral or Negative response24 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsPositive (favorable) response45 Participants
Treatment Group - 2 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsNeutral or Negative response3 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayPositive (favorable) response14 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessNeutral or Negative response17 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingPositive (favorable) response38 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightNeutral or Negative response20 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsNeutral or Negative response2 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingNeutral or Negative response10 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsPositive (favorable) response46 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsPositive (favorable) response17 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightPositive (favorable) response28 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsNeutral or Negative response31 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepPositive (favorable) response26 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysPositive (favorable) response26 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepNeutral or Negative response22 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityPositive (favorable) response26 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayNeutral or Negative response34 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityNeutral or Negative response22 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysNeutral or Negative response22 Participants
Treatment Group - 4 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessPositive (favorable) response31 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityPositive (favorable) response29 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysNeutral or Negative response27 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsNeutral or Negative response28 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessNeutral or Negative response14 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightNeutral or Negative response25 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepPositive (favorable) response28 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 1: Difficulty falling asleepNeutral or Negative response19 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingPositive (favorable) response40 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayPositive (favorable) response14 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsNeutral or Negative response2 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 2: Nasal spraysPositive (favorable) response20 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 6: Having a good sense of overall well-beingNeutral or Negative response7 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 2: Good sleep throughout the nightPositive (favorable) response22 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 3: Feeling fatigued during the dayNeutral or Negative response33 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 5: Feelings of embarrassment or self-consciousnessPositive (favorable) response33 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 1: Oral medicationsPositive (favorable) response19 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 1, Item 4: Feelings of frustration/restlessness/irritabilityNeutral or Negative response18 Participants
Treatment Group - 12 Week DataResponse on Aerin Quality-of-Life (QOL) Assessment ItemsSection 2, Item 3: Nasal breathing stripsPositive (favorable) response45 Participants
Other Pre-specified

rTNSS Responder Rate

The Reflective Total Nasal Symptom Score (rTNSS) is a patient self reported questionnaire of four nasal symptoms: rhinitis, nasal congestion, nasal itching and sneezing. Patients report their symptoms reflected or felt over the last 12 hours. Total scores can range from 0 to 12. A higher score indicates increased symptom severity. Subjects who showed at least a 1 point improvement (decrease) in the reflective Total Nasal Symptom Score (rTNSS) were categorized as responders. An overall responder rate of at least 55% was expected.

Time frame: Comparison of scores at Baseline and 12 weeks post procedure

Population: The analyzed population excludes one subject who did not complete the rTNSS questionnaire at the 12 week follow-up visit due to oversight.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
InSeca Stylus Treatment GrouprTNSS Responder Rate46 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026